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Cancer biology
InvasionThe use of 3-dimensional (3D) collagen gels has yielded new insights into themigratory behaviour of cancer cells.
While the large GTPase dynamin has emerged as an important regulator of cancer cell migration and invasion
under 2D conditions, its role in 3D migration is unclear. We have used a potent dynamin modulator, a bis-
tyrphostin derivative, Ryngo® 1-23, to investigate the role of dynamin in 3D migration in 3 different cell lines.
The compound speciﬁcally inhibits persistent, elongated 3D migration in U87MG and SMA-560 cells. Treated
U87MG cells adopt a rounded morphology that is not due to apoptosis, loss of matrix metalloprotease activity
or inhibition of clathrin-mediated endocytosis. Given that Ryngo 1-23 is known to regulate dynamin
oligomerisation and actin dynamics at the leading edge, we analysed actin ﬁlament distribution. Ryngo 1-23 in-
duced a switch in actin ﬁlament organization in 3D cultures resulting in the generation of multiple short actin-
rich microspikes. Correlated with the change in actin ﬁlament distribution, cells displayed reduced collagen gel
contraction. Since acto-myosin force transmission to the extra-cellular matrix underpins persistent, elongated
migration, our results suggest that Ryngo 1-23 modulates this process in 3D migration via dynamin-mediated
regulation of acto-myosin force transmission to the extra-cellular matrix.
Crown Copyright © 2014 Published by Elsevier B.V. All rights reserved.1. Introduction
The progression to invasive, metastatic disease remains a major im-
pediment to the successful treatment of cancer. Thus there have been
intensive research efforts to identify the molecules and mechanisms
that underpin the migratory ability of invasive cancer cells. While
much work has been done using cells grown on planar 2-dimensional
(2D) surfaces, it is increasingly realized that the 3D tissue structure sur-
rounding cancer cells in vivo is an important determinant of cell migra-
tion behaviour [1–4]. Therefore the use of 3D culture models imparts
important physiological insights into cancer cell migration. The large
GTPase dynamin has emerged as an important regulator of cancer cell
invasion [5], but to date the role that this protein plays in the negotia-
tion of a 3D tissue architecture is not understood.
In a 3D matrix cells must generate contractile force through their
actin cytoskeleton, transmit this force via adhesion to the matrix and
then either deform themselves in order to squeeze through pores innit, KidsResearch Institute, The
ead 2145, Australia. Tel.:+612
.M. O'Neill).
r B.V. All rights reserved.the matrix, or alternatively, secrete proteases to degrade the matrix
and thereby create space for the cell body [6]. The greater the adhesion
force the cell can transmit to the surroundingmatrix the faster they can
move through the 3D matrix and the greater their directional persis-
tence [7]. In the transition zonebetween the lamellipodia and the lamel-
la where focal adhesions form, a molecular clutch has been proposed to
form between the focal adhesions and the actin ﬁlaments [8]. This
clutch facilitates acto-myosin force transmission to the extra-cellular
matrix and thus regulates forward cell movement. Cancer cells charac-
teristically adopt different morphologies reﬂecting their response to
the constraints imposed by a 3D matrix [1,2]. The two most commonly
described morphologies are an elongated/mesenchymal cell shape ver-
sus a rounded/amoeboid cell shape. During elongated cell migration,
cells secrete matrix metalloproteases and pull themselves forward by
attaching to matrix ﬁbres. In contrast, rounded invasion is considered
to be adhesion-independent and depends on a highly contractile acto-
myosin cytoskeleton that produces membrane blebs which allow cells
to squeeze through pores in the matrix.
In addition to these well-described 3D invasion behaviours (and
other alternative modes [9]) we showed that rounding can be induced
by elevated expression of the actin accessory protein tropomyosin
Tm5NM1 [10,11]. This induces a prominent change in the organization
of actin ﬁlaments in 3D, with cells displaying multiple actin-rich
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elevated Tm5NM1 expression leading to cell rounding and microspike
formation, cells become non-motile. Thus actin ﬁlament organization
in 3D culture conditions reﬂects different cellular motility outcomes.
Functional dynamin GTPase is formed via the association of subunits
in a tetramer that further organizes into a helical polymer [5]. The
tetramer structure facilitates dynamin interaction with the neck of
clathrin-coated pits during vesicle endocytosis. Dynamin oligomers
also associate with, and elongate, actin ﬁlaments [12,13]. Correspond-
ingly, many studies show that dynamin plays a role in actin cytoskeletal
dynamics [5,14,15]. Recent studies suggest that dynamin 2may regulate
the molecular clutch at the leading edge of motile cells [16]. Reducing
dynamin function by siRNA-mediated depletion, dominant negative
dynamin II expression and dynamin chemical inhibitors (dynasore
and myristyl trimethyl ammonium bromide (MiTMAB™)) all reduce
2D cell migration and transwell Matrigel invasion [17,18]. Dynamin
also regulates the endocytic delivery ofmembrane-typematrixmetallo-
proteinase 1 to the cell surface, for the conversion of the pro-formof the
matrix-metalloproteaseMMP-2 to active MMP-2 [19] that is important
for elongated cell migration in 3D culture. Endocytosis-mediated turn-
over of focal adhesions to the extra-cellular matrix and actin ﬁlament
dynamics are also critical to elongated cell migration and are each reg-
ulated by dynamin [13,20,21]. Finally, dynamin plays a role in the acti-
vation of Arp2/3 [22] that is required for actin ﬁlament branching and
membrane extension at the leading edge [23]. Collectively, these data
suggest that dynamin may play a role in regulating elongated 3D
migration.
To study dynamin in cellular functions there is now an array of small
molecules targeting different aspects of dynamin function available,
including Ryngo 1-23 (2-cyano-N-{3-[2-cyano-3-(3,4,5-trihydroxy-
phenyl) acryloylamino]propyl}-3-(3,4,5 trihydroxyphenyl) acrylamide)
(previously named bis-T-23 [24]). The inhibitory activity of Ryngo 1-23
that solely occurs in vitro [24] is contrastedwith effects reported in vivo.
In cells, Ryngo 1-23 has been demonstrated to promote dynamin oligo-
merization and thus stimulate the basal GTPase activity of dynamin
[12]. Speciﬁcally, Ryngo 1-23 stimulates actin-dependent dynamin olig-
omerization at the cell's leading edge, in the transition zone between
the lamellipodium and the lamellae, where the molecular clutch be-
tween actin and adhesion is engaged [12]. Thus, Ryngo 1-23 is a useful
agent for investigating the role of actin-dependent dynamin oligomeri-
zation in cellular processes [12]. In the present study we have used
Ryngo 1-23 to investigate the function of dynamin in 3D cell migration.
2. Materials and methods
2.1. Cell culture, antibodies and reagents
Rat neuroblastoma (B35), human glioblastoma (U87MG), and
human ﬁbrosarcoma (HT1080) cell linesweremaintained in Dulbecco's
Modiﬁed EaglesMedium (DMEM) (Invitrogen) supplementedwith 10%
Foetal Bovine Serum (FBS). Growth of cells in 3D collagen gels and
media for live imaging has been previously described [11]. MMP-2pro-
and active enzymes (Calbiochem,Merck)were used as positive controls
for zymography. Stock solution of Ryngo® 1-23 [25] and Dynole® 34-2
[26] were prepared in DMSO.
2.2. Live cell imaging, migration analysis and collagen gel contraction
Cellswere seeded in 3Dcollagen gels (1.7mg/ml) in 24well plates at
a density of 3 × 105 cells per ml with 500 μl of cell/collagen solution per
well. Collagen was polymerised for at least 1 h prior to the addition of
1 ml of DMEM containing 10% FBS. Following overnight incubation,
complete media were exchanged for 500 μl of serum-freeDMEM con-
taining dynamin targeting compounds. DMSO in all controls and drug-
treated wells was maintained at 1% v/v. Following incubation at 37 °C
for 30 min cultures were supplemented with an equal volume of CO2-independent media containing 10% FBS for live cell imaging. Time-
lapse images were captured over a period of 5 h using an ORCA ERG
cooled CCD camera (Hamamatsu, SDR Clinical Technology NSW,
Australia) and an Olympus IX81 inverted microscope (Olympus)
equipped with an environmental chamber heated to 37 °C. Transmitted
light images were captured using a 20× objective. Cells undergoing di-
vision or apoptosis were excluded from analyses. Nuclear translocation
was tracked in time-lapse image stacks usingMetamorph V6.3 software
(Molecular Devices, Sunnyvale, CA, USA). Directional persistence was
calculated from Mean Squared Displacement (MSD) of cells versus
time as previously described [6]. Relative cell elongation was deter-
mined by measuring the longest cell axis at the beginning and at the
end of time lapse imaging. Quantiﬁcation of cell viability was performed
by direct addition of 10 μM propidium iodide to 3D cell cultures. Viable
cells were identiﬁed by exclusion of propidium iodide. Analysis of colla-
gen gel contraction was performed as previously described [27].
2.3. Confocal microscopy
U87MG cells seeded in 3D collagen gels were ﬁxed with 4% para-
formaldehyde in phosphate buffered saline (PBS) and then stained with
ﬂuorescently-tagged phalloidin. Cell nuclei were counter-stained with
prolong gold containing DAPI (Molecular Probes, Invitrogen) and
examined using a FluoView FV1000 confocal microscope (Olympus,
Walkersville, NY, USA) with a UPLSAPO 60_NA1.2 water-immersionlens.
TRITC–phalloidin was detected with a 559 nm laser set at
16.5% and DAPI with a 405 nm laser set at 42%. Imaging was
performed with a 10 ms/pixel sampling speed. Images were
captured at 1024 × 1024 pixel resolution at 0.5 μm intervals.
Final micrograph images were prepared using Photoshop C2S (Adobe,
San Jose, CA, USA).
2.4. MMP-2 zymography
Cell supernatants and pro- and activeMMP-2 standards (Calbiochem,
Darmstadt, Germany) were assayed for gelatinase activity using a
zymography assay. Brieﬂy, electrophoresis was performed on 10% SDS-
PAGE containing 1 mg/ml gelatin. Gels were washed in 2.5% (v/v) Triton
X-100 and incubated overnight at 37 °C in enzyme activation buffer
(50 mM Tris-HCl, 200 mM NaCl, 0.02% (v/v) Tween 20 and 5 mM
CaCl2, pH 7.3). Gels were stained with Coomassie blue solution,
destained and MMP-2 activity visualized as clear bands on a dark
background.
2.5. Clathrin-mediated endocytosis
Assay of clathrin-mediated endocytosis was performed in a 96-well
plate format as described previously [26]. Brieﬂy, cells were grown and
incubated with the drugs or vehicle for 30 min prior to the addition of
A594-conjugated transferrin (Tfn-A594) for 8 min at 37 °C. Cell surface
bound transferrin was removed by a low pH acid wash and the cells
were then ﬁxed with paraformaldehyde. Tfn uptake was quantitated
using an automated acquisition and analysis system (ImageXpress
Micro (IXM), Molecular Devices, Sunnyvale, CA, USA). The average inte-
grated intensity of Tfn-A594 was determined and the data were
expressed as percentage of control.
2.6. Statistical analysis
All error bars on graphs represent the standard error of the mean
(S.E.M.). Statistical comparison of two means was performed by using
a Student's t-test, calculated using Excel (Microsoft, Redmond, WA,
USA) and a comparison of more than two means was performed using
one-way ANOVA with Tukey's multiple comparison test, in Prism V4
software (GraphPad Software, La Jolla, CA, USA).
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3.1. Ryngo 1-23 inhibits glioblastoma 3D migration
The selected cell lines were the U87MG glioblastoma, B35 neuro-
blastoma and HT1080 ﬁbrosarcoma cells, each of which has been
shown to adopt the elongated migration mode in 3D collagen gels [11,
28]. We ﬁrst compared the behaviour of each line in 3D culture. B35
cells extend a thick, leading edge protrusion that displays multiple
spikey projections at the tip (Fig. 1A & Supplementary Movie 1). The
trailing edge is typically rounded and the cell body frequently displays
a peanut-shell shape, suggestive of cell body constriction by surround-
ingmatrix ﬁbres (Fig. 1B arrowheads). TheHT1080 cells have previous-
ly been reported to display a mixed morphology in 3D culture [29] and
similarly in our culture conditions approximately 50% of HT1080 cells
display an elongated phenotype [11]. The elongated HT1080 cells
move through the gels extending long thin extensions at both the lead-
ing edge and trailing edges (Fig. 1A). Matrix ﬁbres in advance of the
leading edge are pulled in the direction of the cell, as the cells appear
to tug on the collagen ﬁbres (Fig. 1C, Supplementary Movie 2). At the
rear a migration track is seen, where the cell has degraded and
rearranged the matrix as it has created a path (Fig. 1C). The U87MGFig. 1. Elongated 3D migration. (A) Bright-ﬁeld time-lapse images of B35, HT1080 and U87MG
showing cell body constriction (arrow heads). (C) HT1080 cell showing the displacement of c
(green arrow heads).cells also extend a long thin leading edge projection, although, in con-
trast to theHT1080 elongated invasionmorphology, theU87MG leading
edge is frequently a singlemono-polar extension and the trailing edge is
rounded (Fig. 1A & Supplementary Movie 3). Similar to the HT1080
cells, the U87MG cells also displace local collagen ﬁbres and in both
cell lines it is possible to visualize tracks where the matrix has been
rearranged as a cell has passed through. The U87MG cells move most
rapidly through the gel, with an average speed of 0.48 ± 0.03 μm/min,
compared with 0.23 ± 0.01 μm/min and 0.25 ± 0.01 μm/min for the
B35 and HT1080 cells, respectively. Moreover, not all cells in the popu-
lation are motile with the percentage of motile cells ranging from
60% ± 16 (HT1080), 69% ± 0.9 (U87MG) and 71% ± 7.3 (B35). Collec-
tively, these data reveal that although each cell line displays an elongat-
ed mode of invasion, there are differences in their response to the
external matrix organization.
We next determined the effect of Ryngo 1-23, a compound that pro-
mote dynamin's natural propensity to oligomerise andwhich stimulates
its basal GTPase activity [12], on the 3Dmigratory behaviour of each cell
line. Analysis of time-lapse series of cells treated with increasing con-
centrations of Ryngo 1-23 revealed that the total percentage of motile
cells was not signiﬁcantly affected in either the B35 or HT1080 cells
lines, at any concentration tested (Fig. 2A). In contrast, the percentagecells in 3D collagen gels. Time shown in hours and minutes. Scale bar 50 μm. (B) B35 cell
ollagen ﬁbres at the leading edge (blue lines) and the migration track at the trailing edge
Fig. 2. Ryngo 1-23 inhibits U87MG 3D migration. (A) Percentage of motile cells in the different cell types under the indicated conditions. Graph shows the mean of three independent
experiments. (B) Average cell speeds. Data show the average of four independent experiments, n ~ 30 cells tracked per condition, per experiment. *p b 0.05, **p b 0.01, ***p b 0.001.
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testedwas signiﬁcantly reduced (Fig. 2A).Moreover, Ryngo 1-23 caused
a concentration-dependent reduction in U87MG 3D migration speed
(Fig. 2B), but not in the B35 or HT1080 cells (Fig. 2B). U87MG cells treat-
ed with Ryngo 1-23 lost their elongated phenotype (Fig. 3A). Quantita-
tive analysis conﬁrmed that cell elongationwas signiﬁcantly reduced at
both 10 and 100 μMRyngo 1-23 concentrations inU87MG cells (Fig. 3A)
but there was no change in the morphology of B35 or HT1080 cells at
any concentration examined (Supplementary Movies 1 and 2). The
reduced migration and increased rounding in the U87MG cells were
not due to apoptosis or changes in proliferation in response to Ryngo
1-23, as both apoptotic and mitotic cells were excluded from analyses
(as determined by cell morphology). Separately, quantiﬁcation of
U87MG cell viability by propidium iodide dye exclusion revealed no dif-
ference in cell viability at the highest concentration of Ryngo 1-23 used
in this study (Fig. 3B). Notably, the motile Ryngo 1-23-treated cells useFig. 3. Ryngo 1-23 reduces U87MG elongation. (A) Brightﬁeld time-lapse series of U87MG cel
shows elongation ratios (expressed relative to controls) following 5 h of treatment with the
cell length at zero time point to cell length after 5 hour treatment with Ryngo 1-23. Data are
cells was unaffected by Ryngo 1-23 exposure as measured by propidium iodide dye exclusio
(C) Motile cells retain an elongated phenotype, but move more slowly through the gel. Montathe same elongated migration mode as their control counterparts
(Fig. 3C and Supplementary Movie 4, note that this movie is double
the length of time as the control cell shown in Supplementary Movie
3). In contrast the spherical cells are essentially non-motile (Supple-
mentary Movie 5).
We next askedwhether Ryngo 1-23might also reduce the 3Dmigra-
tion of other glioblastoma cells. The SMA-560 mouse glioblastoma cells
are similar to the U87MG cells in that they invade brain tissue in vivo
[30] and are likely to employ similar invasionmechanisms. As observed
with U87MG cells, the SMA-560 cells displayed a concentration-
dependent reduction in 3D cell speed following treatment with Ryngo
1-23 (Fig. 4A). Given that the untreated SMA-560 cells had similar
speed to the B35 and HT1080 cells (0.2 ± 0.02 μm/min) we compared
the movement of SMA-560 cells with these lines. Comparison of the
Mean Squared Displacement (MSD) for each cell line revealed that
both the B35 and HT1080 curves crossed over the SMA-560 MSDls in 3D collagen gel, time shown in minutes after treatment with Ryngo 1-23. Histogram
indicated concentrations of Ryngo 1-23. Elongation ratios were measured by comparing
the mean values from three independent experiments. *p b 0.05. (B) Viability of U87MG
n following 5 hour treatment with either control DMSO media or 100 μM Ryngo 1-23.
ge shows U87MG cells treated with 10 μm Ryngo 1-23.
Fig. 4. Ryngo 1-23 inhibits 3D migration of SMA-560 glioblastoma cells. (A) Average SMA-560 cell speeds in the indicated concentrations of Ryngo 1-23. Data show the average of four
independent experiments, n ~ 30 cells tracked per condition, per experiment. (B) MSD calculated from the trajectories of U87MG, SMA-560, B35 and HT1080 cells in 3D collagen gels.
Data are the average values from at least 4 independent experiments, n = 30 cells tracked per experiment. (C) Examples of the migration tracks taken by SMA-560 and B35 cells. Each
time point is indicated by a white spot and the distance travelled between consecutive time point is indicated by the joining lines. Shown are examples of 15 individual cells from each
cell line. (D) B35 and HT1080 cells are signiﬁcantly less directionally persistent than SMA-560. (E) Elongation ratios (expressed relative to controls) following 5 h of treatment with
the indicated concentrations of Ryngo 1-23. (D) *p b 0.05, **p b 0.01, ***p b 0.0001, NS = not signiﬁcant.
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al persistence (Fig. 4B). This behaviour is emphasized by analysis of
paths traced by the SMA-560 and B35 cells. While the SMA-560 tended
to more consistently move in one direction, the B35 cells frequently
changed direction, moving back over the same area (Fig. 4C). Calcula-
tion of the persistence conﬁrmed that the SMA-560 cells are signiﬁcant-
ly more directionally persistent than either the B35 or HT1080 cells
(Fig. 4D). This data indicates that despite the similar overall speed
between the B35, HT1080 and SMA-560 cells, they employ different
strategies to move through the 3D gels. Moreover, similar to the
U87MG cells, SMA-560 elongation was reduced in the highest concen-
tration of Ryngo 1-23 used (Fig. 4E).
3.2. Ryngo 1-23 does not affect MMP activity or clathrin-mediated
endocytosis
A switch from elongated to rounded cell morphologies in 3D colla-
gen gels has previously been shown to occur in response to theFig. 5. Cell rounding is not due to inhibitedMMP-2 activity. (A) Gelatin zymography ofMMP-2. G
1) and activeMMP-2 (lane 2). MMP-2 levels in conditionedmediawith 1%DMSO and cell-free c
respectively. Lanes 5 and6 showMMP-2 in conditionedmedia from collagengels containingU87
active MMP2 (lanes 5 and 6) was seen in three independent experimental repeats, but levels w
MMP-2 levels under the indicated conditions, expressed relative to levels in the control. Bars sinhibition of matrix metalloprotease (MMP) activity [29]. As dynamin
regulates the pro-MMP-2 conversion to active MMP via delivery of
membrane-type MMP-1 to the cell surface [19] and MMP-2 activity is
associated with glioblastoma migration and invasion [31,32], we asked
whether the rounded phenotype and reduced migration speed might
reﬂect Ryngo 1-23 effects on MMP activity. Analysis of MMP-2 activity
by gelatin zymography revealed that there was no signiﬁcant difference
in the amount of secreted pro-MMP-2 in cells treated with Ryngo 1-23
when compared withmatched controls (Fig. 5A and B). Although levels
of the active form ofMMP-2were too low for accurate quantiﬁcation by
densitometry, in 3 separate experiments faint bandswere observed and
no differences seen between control cell cultures versus cultures
exposed to Ryngo 1-23 (Fig. 5A). Therefore Ryngo 1-23 does not alter
U87MG 3D migration via inhibition of MMP-2 function.
Dynamin also mediates clathrin-mediated endocytosis, which is a
critical determinant of cell migration. Therefore we analysed Ryngo
1-23 effects on endocytosis in the U87MG cells, using brief uptake
of ﬂuorescently-labelled transferrin in response to increasingelswere loadedwith puriﬁed pro-MMP-2 (both the pro- and active forms are visible, lane
ollagen gels in the absence and presence of 100 μMRyngo 1-23 are shown in lanes 3 and 4,
MG cells in the absence andpresence of 100 μMRyngo1-23, respectively. Similar low level
ere too low for densitometric analysis. (B) Graph showing densitometric analysis of pro-
how the average from three independent experiments. **p b 0.01, NS = not signiﬁcant.
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only ~20%maximal inhibition observed at the highest concentration
used (Fig. 6A). For comparison, we also analysed the effect of Ryngo
1-23 on transferrin uptake in B35 cells and found that Ryngo 1-23
also did not inhibit endocytosis in these cells (~20% maximal
inhibition, Fig. 6A). The efﬁcacy of the transferrin endocytosis
assay was independently conﬁrmed using the well characterised
dynamin inhibitor Dynole™ 34-2 that has previously been shown
to inhibit clathrin-mediated endocytosis [33]. Dynole 34-2 efﬁcient-
ly inhibited endocytosis in both the U87MG (IC50 of 34.5 ± 10.8 μM)
(Fig. 6B) and B35 cells (IC50 of 6.6 ± 2.6 μM) (Fig. 6B). Therefore
Ryngo 1-23 inhibition of U87MG 3D migration is not due to inhibi-
tion of endocytosis.
3.3. Ryngo 1-23 alters glioblastoma adhesion to the matrix
Based on the emerging role for dynamin in regulating the actin
cytoskeleton [12], we next considered whether the altered cell mor-
phologies in response to Ryngo 1-23 might reﬂect changes in actin ﬁla-
ments. Prominent bundles of ﬁlamentous actin were observed at the
lateral edges of extendingmembraneprocesses and in trailing processes
in control U87MG cells (Fig. 7A). In addition, thin, short actin ﬁlaments
were observed extending into the leading edge of the extending
membrane process. In contrast, signiﬁcantly fewer U87MG cells
displayed extended protrusions at concentrations of N10 μM Ryngo 1-
23 (Fig. 7A). Instead, these spheroid-shaped cells frequently displayed
actin-rich microspikes emanating from all over the cell body (Fig. 7A).
3D projections of the phalloidin-stained cells emphasize the differences
in actin organization between control cells and cells exposed to Ryngo
1-23 (Supplementary movie 6). The actin cytoskeleton is intimately
involved in the adhesion of the cells to the matrix and the migrating
U87MG cells display prominent tugging on the matrix ﬁbre. Therefore
we asked whether the actin cytoskeleton changes following exposure
to Ryngo 1-23 might reﬂect a change in the contractile force exerted
by the cells through adhesion to the matrix. To test this we performed
a collagen contraction assay (Fig. 7B). This revealed signiﬁcantlyFig. 6. Ryngo 1-23 does not inhibit clathrin-mediated endocytosis. (A) Quantiﬁcation of labelled
(B) Labelled transferrin uptake following exposure to Dynole 34-2 as indicated. Error bars reprreduced gel contraction at 100 μM Ryngo 1-23 (Fig. 7C). Using
propidium iodide staining we conﬁrmed that the reduced contractility
was not due to an increase in apoptosis (Fig. 6D). Together this suggests
that Ryngo 1-23 treatment of U87MG reduces the adhesive forces that
the cells exert on the surrounding matrix.
4. Discussion
Accumulating studies have suggested that dynamin may be an im-
portant target for the development of anti-invasive therapies for meta-
static cancer [17,18,34]. Due to the increasing understanding of how
cancer cells can adopt a range of migratory strategies to negotiate com-
plex 3D extra-cellular environments [1] it is critical to use 3D culture
methods to investigate the efﬁcacy of compounds for blocking cancer
cell migration and invasion. The results of our study demonstrate that
the small molecule dynamin modulator Ryngo 1-23 suppresses the 3D
cell migration speed of the glioblastoma cell lines U87MG and SMA-
560. Our ﬁndings conﬁrm that dynamin indeed plays a role in cell nego-
tiation of a 3D extra-cellular environment.
Comparison of the 3Dmigration behaviours of the B35 neuroblasto-
ma, HT1080 ﬁbrosarcoma and U87MG cells revealed important differ-
ences. Analysis of the B35 cells revealed constriction by the local
collagen ﬁbres. Similar phenotypes were infrequently seen in the
HT1080, SMA-560 and U87MG cells. Moreover, while the B35 cells
also tugged on the ﬁbres ahead of the cell, ﬁbre displacement was
much less than that observedwith the other two cell lines. This suggests
a greater adhesion to the surroundingmatrix ﬁbres by both the HT1080
and U87MG cells. The fact that the U87MG cell speed is almost double
that of the HT1080 cells further suggests that these cells exert an even
greater adhesive force on the surrounding ﬁbres than the HT1080
cells. Previous studies have also revealed differences between the
behaviour of U87MG and HT1080 cells in 3D collagen [28]. While the
SMA-560movemore slowly than the U87MG cells, the enhanced direc-
tional persistence when compared with the B35 and HT1080 cells indi-
cates a stronger adhesive force in these cells. Since Ryngo 1-23 inhibited
3Dmigration of U87MG (fast and persistent) and SMA-560 (persistent)transferrin uptake at the indicated concentrations of Ryngo 1-23 in U87MG and B35 cells.
esent SEM of three independent experiments, each performed in triplicate.
Fig. 7. Ryngo 1-23 disrupts the actin cytoskeleton and reduces collagen gel contraction. (A) Percentage of spheroid shaped U87MG cells. Micrographs show examples of cells that were
ﬁxed, permeabilized and stained with ﬂuorescently-labelled phalloidin to detect ﬁlamentous actin. Arrowheads in control cells indicate actin ﬁlaments (stress ﬁbres) in the body of the
elongated cell and along the cell perimeter. Arrowheads in Ryngo 1-23 indicate actin-rich microspikes. (B) Collagen gel contraction assay. Images show examples of gels containing
U87MG cells released from the wells and then incubated for 5 days. Arrows indicate gel diameters. (C) Area of released collagen expressed relative to area of gel in the absence of
drug. ***p b 0.001, one-way ANOVA with Tukey's post-comparison test.
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that depends on strong adhesion to the extra-cellular matrix.
We tested known dynamin functions to determine whether these
functions could account for Ryngo 1-23 inhibition of 3D migration and
induce rounding. The changes are not due to apoptosis, MMP inhibition
nor clathrin-mediated endocytosis. It was surprising that Ryngo 1-23
did not inhibit transferrin uptake, as previous studies have shown that
Ryngo 1-23 inhibits transferrin uptake in dendritic cells [35]. The differ-
ences may reﬂect the bulk endocytosis assay based on FACS used in the
latter study, rather than the better characterised acute CME assay used
here. Cell type speciﬁcity may also play a role, given that the dendritic
cells are professional scavengers. Alternatively, the difference may
reﬂect concentration-speciﬁc effects. While 100 μM Ryngo 1-23 was
sufﬁcient to inhibit endocytosis in dendritic cells [35] but not in
U87MG cells, it is possible that higher concentrations of the compound
may inhibit U87MG endocytosis. Nonetheless, since signiﬁcant inhibi-
tion of 3D migration speed occurred at concentrations as low as 1 μM,
inhibition of endocytosis cannot be the cause of reduced 3D migration
in U87MG cells. Therefore Ryngo 1-23 inhibits U87MG motility by a
mechanism that is unrelated to dynamin's function in endocytosis.
Dynamin plays a role in remodelling actin ﬁlaments and thereby
inﬂuencing global actin cytoskeletal structure via either indirect mech-
anisms including interactionswith cortactin [36] and regulating the dis-
assembly of focal adhesions that anchor actin ﬁlaments [21,37], or
directly by interacting with short actin ﬁlaments to stimulate their
uncapping and elongation [13]. Dominant negative dynamin, deﬁcientin the binding and hydrolysis of GTP, is known to alter both cell shape
and cytoskeletal structure, causing a redistribution of stress ﬁbres to
the cell periphery [38]. Further, contractility of the actomyosin cytoskel-
eton is required for cells to exert force through the associated focal
adhesions onto the surrounding matrix in order to translocate the cell
body [39]. Our data reveal that Ryngo 1-23 induces altered actin ar-
rangement and a corresponding reduction in the associated adhesive
force to the extra-cellular matrix. Potentially, this reﬂects reduced abil-
ity of the cells to extend newmembrane in order to formnew adhesions
to matrix ﬁbres ahead of the cell. Rac GTPase-mediated activation of
Arp2/3 is critical to the generation of short branched actin ﬁlaments
that push the membrane forward [23]. It is therefore interesting that
Rac inhibition differentially affects HT1080 versus U87MG cell 3D inva-
sion [28]. While Rac inhibition induces amoeboid transition in HT1080
cells, U87MG cells instead display repressed actin polymerisation at
the tips of leading edge membrane protrusions. Our data reveals that
Ryngo 1-23 speciﬁcally inhibits the elongated, directional mode of 3D
migration exhibited by the U87MG and SMA-560 cells. Notably, a recent
study using dynamin triple knockout cells revealed that the effects of
one dynamin inhibitor compound include at least one off-target effect
[40]. Thus it remains possible that Ryngo 1-23 may be affecting other
targets. However, the off-target issue is not a problem limited to the
use of small molecules as cell biology probes. The problem is potentially
more signiﬁcant in genetically manipulated cells where transfections
and/or knockdowns occur for days instead of minutes, and have many
off-target actions on other proteins which can be down-regulated [41]
618 J.G. Lees et al. / Biochimica et Biophysica Acta 1853 (2015) 611–618or mislocalised in the cell [40]. Nonetheless, Ryngo 1-23 has been
shown to induce actin-dependent dynamin oligomerization at the cell's
leading edge [12] and dynamin regulates the actin/adhesion molecular
clutch at the leading edge [16]. Thus we propose that Ryngo 1-23 mod-
ulates the actin/adhesion clutch, thus reducing the transmission of the
acto-myosin force required for elongated, persistent movement in a
3D environment.
Our study has revealed that the dynaminmodulating smallmolecule
Ryngo 1-23 signiﬁcantly inhibits U87MG and SMA-560 glioblastoma
cell 3D migration speed. Collectively, our data reveal an important
non-endocytic function for dynamin in 3D cell migration, but suggests
a speciﬁc role in the elongated cell invasion that depends on the forma-
tion of actin stress ﬁbres required to transmit cellular force in order to
move through the 3D matrix.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.12.008.
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